Pharmaceuticals, Biotechnology and Life Sciences
Roche on Wednesday reported 10% raise in sales in the third yearly quarter of 2019, backed by new products, while its Pharmaceuticals Division sales went up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta.
Roche will present a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients…
– New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment –…
Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
– Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented…
Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%…
– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in…
Synlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical…